AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-Β-mediated ERK signaling

Article (PDF Available)inOncogene 29(37):5146-58 · September 2010with38 Reads
DOI: 10.1038/onc.2010.258 · Source: PubMed
Epithelial-to-mesenchymal transdifferentiation (EMT) mediated by transforming growth factor-β (TGF-β) signaling leads to aggressive cancer progression. In this study, we identified zinc-α2-glycoprotein (AZGP1, ZAG) as a tumor suppressor in pancreatic ductal adenocarcinoma whose expression is lost due to histone deacetylation. In vitro, ZAG silencing strikingly increased invasiveness of pancreatic cancer cells accompanied by the induction of a mesenchymal phenotype. Expression analysis of a set of EMT markers showed an increase in the expression of mesenchymal markers (vimentin (VIM) and integrin-α5) and a concomitant reduction in the expression of epithelial markers (cadherin 1 (CDH1), desmoplakin and keratin-19). Blockade of endogenous TGF-β signaling inhibited these morphological changes and the downregulation of CDH1, as elicited by ZAG silencing. In a ZAG-negative cell line, human recombinant ZAG (rZAG) specifically inhibited exogenous TGF-β-mediated tumor cell invasion and VIM expression. Furthermore, rZAG blocked TGF-β-mediated ERK2 phosphorylation. PCR array analysis revealed that ZAG-induced epithelial transdifferentiation was accompanied by a series of concerted cellular events including a shift in the energy metabolism and prosurvival signals. Thus, epigenetically regulated ZAG is a novel tumor suppressor essential for maintaining an epithelial phenotype.
    • "TritonX-100/PBS for one hour at RT, incubated with the primary antibodies, overnight at 4°C. For the TGFβ signaling cascade, the following antibodies were purchased commercially: anti-Smad2 (D43B4) rabbit mAb (1:100 dilution, Cat#5339) [19], anti-Smad2/3 (D7G7) Rabbit mAb (1:100 dilution, Cat# 8685) [20], anti-Smad3 (C67H9) rabbit mAb (1:100 dilution, Cat# 9523) [21], anti-Smad4 (cat#9515) [22], anti-Phospho-Smad2 (Ser465/467) (138D4) rabbit mAb (1:100 dilution, cat#3108) [23], and anti-phospho-Smad3 (Ser423/425) (C25A9) rabbit mAb (1:100 dilution, Cat#9520) [24] from Cell Signaling Technology, Beverly, MA. For cell proliferation activity, the following antibodies were purchased commercially: anti-Proliferating cell nuclear antigen (PCNA) PCNA (1:2400 dilution, cat# #8607) [25], anti-Histone H3 (D1H2) rabbit mAb (1:100 dilution, Cat#4499) [26], anti-phospho-Histone H3 (Thr3) (cat#9714) [ 27]; anti-phospho-Histone H3 (Thr11) (cat#9764) [ 28], anti-phospho-Histone H3 (Ser28) (1:100 dilution, cat# 9713) [29] from Cell Signaling Technology, Beverly, MA. "
    [Show abstract] [Hide abstract] ABSTRACT: Wounds are among the most common, painful, debilitating and costly conditions in older adults. Disruption of the angiotensin type 1 receptors (AT1R), has been associated with impaired wound healing, suggesting a critical role for AT1R in this repair process. Biological functions of angiotensin type 2 receptors (AT2R) are less studied. We investigated effects of genetically disrupting AT2R on rate and quality of wound healing. Our results suggest that AT2R effects on rate of wound closure depends on the phase of wound healing. We observed delayed healing during early phase of wound healing (inflammation). An accelerated healing rate was seen during later stages (proliferation and remodeling). By day 12, fifty percent of AT2R-/- mice had complete wound closure as compared to none in either C57/BL6 or AT1R-/- mice. There was a significant increase in AT1R, TGFβ1 and TGFβ2 expression during the proliferative and remodeling phases in AT2R-/- mice. Despite the accelerated closure rate, AT2R-/- mice had more fragile healed skin. Our results suggest that in the absence of AT2R, wound healing rate is accelerated, but yielded worse skin quality. Elucidating the contribution of both of the angiotensin receptors may help fine tune future intervention aimed at wound repair in older individuals.
    Full-text · Article · Jan 2016
    • "However, due to the marginal benefit and the severe side effects accomplished with aromatase inhibitor therapy, tamoxifen still plays an important role in breast cancer treatment. Tamoxifen alone is not sufficient in about 30% of these patients [2]. [35] More malignant breast tumors showed downregulated AZGP1 mRNA. [36] Low AZGP1 expression, by IHC, was associated with clinical recurrence in prostate cancer. "
    [Show abstract] [Hide abstract] ABSTRACT: Despite the success of tamoxifen since its introduction, about one-third of patients with estrogen (ER) and/or progesterone receptor (PgR) - positive breast cancer (BC) do not benefit from therapy. Here, we aim to identify molecular mechanisms and protein biomarkers involved in tamoxifen resistance. Using iTRAQ and Immobilized pH gradient-isoelectric focusing (IPG-IEF) mass spectrometry based proteomics we compared tumors from 12 patients with early relapses (<2 years) and 12 responsive to therapy (relapse-free > 7 years). A panel of 13 proteins (TCEAL4, AZGP1, S100A10, ALDH6A1, AHNAK, FBP1, S100A4, HSP90AB1, PDXK, GFPT1, RAB21, MX1, CAPS) from the 3101 identified proteins, potentially separate relapse from non-relapse BC patients. The proteins in the panel are involved in processes such as calcium (Ca(2+)) signaling, metabolism, epithelial mesenchymal transition (EMT), metastasis and invasion. Validation of the highest expressed proteins in the relapse group identify high tumor levels of CAPS as predictive of tamoxifen response in a patient cohort receiving tamoxifen as only adjuvant therapy. This data implicate CAPS in tamoxifen resistance and as a potential predictive marker.
    Full-text · Article · Dec 2015
    • "Staining scores were calculated for both Nodal and Lefty by multiplying values for the intensity of staining (0 ¼ no staining, 1 ¼ weak or medium staining, 2 ¼ strong staining) with values for the stained area (1 ¼ less than one-third stained area, 2 ¼ between one and two-thirds stained area, 3 ¼ more than two-thirds stained area). The total histologic score (0e6) was expressed as a product of the intensity and area scores as previously described [11]. "
    [Show abstract] [Hide abstract] ABSTRACT: Nodal (nodal growth differentiation factor) and its inhibitor Lefty (left right determination factor), which are ligands of the TGF (transforming growth factor) β superfamily, are responsible for the determination of left-right asymmetry in vertebrates. Nodal/Lefty signaling has been suggested to play a role in the development of metastatic melanoma and breast cancer. However, it remains unclear whether this pathway is also involved in human pancreatic ductal adenocarcinoma (PDAC). Pancreatic cancer patient specimens with clinical data (n = 54) were used to investigate the clinical significance of Nodal-Lefty signaling. A set of in vitro assays were carried out in a human pancreatic cancer cell line (Colo-357) to assess the functional relevance of Nodal-Lefty signaling. Nodal was absent in the human normal pancreas, while Lefty was present in islet cells. Though Nodal and Lefty expression were found in cancer cells at various expression levels, the cancer-associated tubular complexes were particularly positive for Lefty. Survival analysis revealed that high expression of Nodal correlated with reduced patient survival (median survival 17.8 vs 33.0 months, p = 0.013). Cultured pancreatic cancer cell lines expressed Nodal and Lefty at different levels. In vitro functional assays revealed that treatment with human recombinant Nodal inhibited cell growth and increased invasion of Colo-357 pancreatic cancer cells whereas no effect was found upon treatment with recombinant Lefty. Nodal-Lefty signaling might be involved in the pathogenesis of PDAC as Nodal expression marks a subtype of PDAC with unfavorable prognosis. Copyright © 2015 IAP and EPC. Published by Elsevier B.V. All rights reserved.
    Full-text · Article · Feb 2015
Show more